by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced.
From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.
hepatocyte growth factor; scatter factor HEPATOCYTE GROWTH FACTOR (HGF) was isolated and named because of its ability to stimulate DNA synthesis in cultured hepatocytes but is now known to have activity on a variety of epithelial cells (14, 18) . Purification of scatter factor, which enhances motility and invasiveness of certain cell types, revealed that it had the same amino acid sequence as HGF (7), leading to the designation HGFSF. HGF/SF is a large, dimeric glycoprotein composed of a 69-kDa a-subunit and a 34-kDa P-subunit. It shares homology with plasminogen, al-' though the amino acids that comprise the active triad in plasminogen have been mutated such that HGF/SF has no known protease activity. HGF/SF is synthesized as an inactive, single-chain zymogen that is cleaved to produce the active, two-chain form (12, 17) .
While studying the effects of HGF/SF in animal models of liver injury (Zl), we found that we could only demonstrate efficacy if HGF/SF was administered intravenously. Similarly, all published reports that have shown efficacy of HGF/SF in vivo have used intravenous delivery (6, 8, 21) . However, this approach is complicated by the fact that HGF/SF is cleared very rapidly (1, 25), so that plasma levels fall rapidly to baseline after each injection. Subcutaneous or intraperitoneal injection is commonly used to produce more prolonged exposure to an exogenous substance, but HGF/SF is very poorly absorbed into the blood when administered by these routes (F. Roos and R. H. Schwall, unpublished observation). Because HGF/SF binds strongly to heparin (19) and extracellular matrix (13), we hypothesized that its low extravascular bioavailability might be due to trapping at the injection site by binding to extracellular matrix. Consistent with this hypothesis, bioavailability was increased if the heparin-binding sites on HGF/SF were saturated with soluble heparin before injection (unpublished observation). The enhancement of HGF/SF bioavailability *was not specific to heparin and was observed with a variety of sulfated polysaccharides, such as pentosan polysulfate, hyaluronate, and dextran sulfate.
Injections were used in the studies described above. The goal of the present work was to determine whether the strategy of blocking heparin binding sites on HGF/SF could be extended into a continuous infusion system to avoid the fluctuating blood levels that occur when injections are used. Dextran sulfate was chosen over heparin because of the anticoagulant activity of heparin. We show that intraperitoneal infusion of HGF/SF with the use of osmotic minipumps containing HGF/SF plus dextran sulfate is indeed an effective mode of delivery. Moreover, administration of HGF/SF in this manner to otherwise normal mice induced proliferation of hepatocytes, growth of liver, and changes in serum biochemistry-MATERIALS AND METHODS
Animals.
Male C3H/HeJ mice were obtained from The Jackson Laboratory (Bar Harbor, ME) at 6-8 wk of age (body wt 23-27 g) and allowed to acclimatize in the animal facility for at least 1 wk. Food (Formulab Chow, Purina Mills) and water were provided ad libitum, room temperature was maintained at 72"F, and rats were maintained on a 12: 
RESULTS
HGF/SF was loaded into osmotic minipumps alone or in combination with dextran sulfate. As noted in the introduction, we had previously found that bioavailability of HGF/SF after subcutaneous or intraperitoneal injection was markedly enhanced when HGF/SF was premixed with dextran sulfate and that a 1:lO ratio of HGF/SF to dextran sulfate was optimal. Therefore, in experiment 1 we used a HGF/SF:dextran sulfate ratio of 1:lO with a HGF/SF dose of 2.4 mg* kg-l-day-l.
We also tested a 1:2 ratio. As shown in Table 1 , plasma levels of immunoactive HGF/SF in experiment 1 were increased when HGF/ SF alone was infused, compared with vehicletreated controls, but there was no effect on wet liver weight. Dextran sulfate alone also had no effect. When HGF/SF was combined with a twofold mass ratio of dextran sulfate, plasma HGF/SF levels were increased further than with HGF/SF alone. Moreover, now there was a significant increase in liver wet weight. There was no effect on serum HGF/SF when the HGF/SF:dextran sulfate ratio was 1:lO (data not shown), but at these concentrations the solution was extremely viscous and probably did not get out of the pump.
In experiment 2, we tested HGF/SF:dextran sulfate ratios of 1:2 and l:l, with the daily HGF/SF dose again fixed at 2.4 mg/kg. As shown in Table 1 , this experiment confirmed the increases in serum HGF/SF levels and liver weight after infusion of HGF/SF with dextran sulfate at a 1:2 mass ratio. Similar effects were also observed at a 1:l ratio. Figure 1 shows the results of a more detailed dextran sulfate dose-response curve tested with and without a 2.4 mg= kg-l l day-l dose of HGF/SF. Again, no effect was observed with dextran sulfate alone at any dose. When HGF/SF was combined with the lowest dose of dextran sulfate (0.24 mgekg-*day-l, a 1:O.l ratio), plasma HGF/SF was increased, but there was only a slight effect on liver weight that was not statistically significant. However, both plasma HGFISF and liver weight increased in a dose-dependent manner with increasing concentrations of dextran sulfate in the pump, with liver weight reaching a plateau between a 1:0.3 and 1:1 ratio. On the basis of these data, a HGF/SF:dextran sulfate ratio of 1:l was used in all subsequent studies. In experiment 3, we tested several different doses of HGFISF (0.27, 0.8, or 2.4 mgakg-l *day-l), with the HGF/SF:dextran sulfate ratio held constant at 1:l. Consistent with earlier experiments, liver weight was increased in the 2.4 mg. kg-loday-l group (6.9 t 0.1% body wt for HGF/SF-treated animals vs. 5.5 t 0.2 for controls, P < O.Ol), but there was no effect at the two lower HGF/SF doses (data not shown). In experiment 4, HGF/SF doses of 1.2, 2.4, and 4.8 mg* kg-l l day-l were tested, again with a fixed 1:1 HGF/SF:dextran sulfate ratio. One control group received pumps containing only the buffer vehicle, and a second control group received dextran sulfate alone at 4.8 mg* kg-l l day-l. As shown in Fig. 2 , serum HGF/SF levels were very low in controls that received neither HGF/SF nor dextran sulfate and in animals given dextran sulfate alone but were increased in a dose-dependent manner when the pumps contained increasing concentrations of HGF/SF with dextran sulfate. Liver weight was increased markedly in both the 2.4 and 4.8 mgekg-l-day-l dose groups compared with controls, and these two groups were not different from each other.
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We repeated these studies several times and, as can be seen in Table 2, enlargement of the liver, measured either as absolute liver weight or normalized to body weight, was observed in every experiment in which the HGF/SF dose was 2.4 mg* kg-l-day-l or greater. The average increase was 27 t 8%. In contrast, there was no effect on the weight of kidney or spleen in any experiment (Table 2) .
On gross examination, livers from control and HGF/ SF-treated animals differed only in size. Histologically, the livers induced to grow by HGF/SF-dextran sulfate looked normal, except that mitotic figures, which were rarely found in sections of control liver, were frequently seen in HGF/SF-treated animals (Fig. 3) . To quantify this effect, we counted the number of mitotic figures in 20 randomly selected fields. The results are shown in Table 3 . An average of one mitotic figure was found throughout all 20 fields from control livers and from livers exposed to either dextran sulfate alone or 1.2 mg. kg-l *day-l HGF/SF. In contrast, approximately 30 figures were found in the 20 fields from livers exposed to higher doses of HGF/SF, nearly two in each field. No mitotic figures were observed in bile duct epithelium. In the two experiments in which it was measured, total liver DNA increased by 21% in experiment 5 and by 34% in experiment 6 (Table 3) , although this effect did not reach statistical significance in experiment 5 (P = 0.14).
Serum samples from HGF/SF-treated animals were frequently lipemic, which led us to measure a panel of serum biochemistries (Table 4) . Consistent with its lipemic appearance, serum triglycerides and cholesterol were markedly elevated in a dose-dependent manner. In addition, total serum protein and serum albumin were increased. Conversely, alkaline phosphatase was reduced by HGF/SF. No effect on either alanine aminotransferase (Table 4) delivered using osmotic minipumps. The rationale for the use of dextran sulfate is that in a separate series of experiments, we found that premixing of HGF/SF with soluble heparin greatly enhanced its bioavailability from subcutaneous and intraperitoneal sites (F. Roos and R. H. Schwall, unpublished observation), an effect that was also observed with other sulfated polysaccharides, including pentosan polysulfate, hyaluronate, and dextran sulfate. Dextran sulfate was chosen for the infusion studies because of the anticoagulant activity of heparin, but we anticipate that similar results would be achieved with any sulfated polysaccharide.
Although we have not defined the mechanism experimentally, we hypothesize that dextran sulfate saturates the heparin binding regions on HGF/SF, thereby preventing interaction with matrix components and trapping of HGF/SF at the infusion site. However, there are other mechanisms that may contribute to the enhancement of HGF/SF efficacy. Heparin and other sulfated polysaccharides may stabilize HGF/SF in a manner analogous to their ability to stabilize acidic fibroblast growth factor against heat and acid denaturation (5). Naka et al. (16) have shown that heparin can enhance the response of isolated hepatocytes to HGF/SF in vitro. In a similar manner, heparin and dextran sulfate cause a left shift in the sensitivity of isolated hepatocytes to HGF/SF in vitro (T. Zioncheck, unpublished observation). Although this effect may be attributed to stabilization, there may also be an effect on the hepatocyte. Lastly, administration of heparin with HGF/SF decreases the clearance of HGF/SF in rabbits (N. Modi, personal communication), and dextran sulfate may have a similar effect on clearance.
The absolute values for plasma HGF/SF varied among experiments. For example, the same dose of HGF/SF and dextran sulfate (2.4 and 4.8 mgakg-l.day-i) produced plasma levels of 28.3 rig/ml in experiment 1 and 7.1 rig/ml in experiment 2 (see Table 1 ). In addition, the plasma levels of HGF/SF achieved by infusion of HGF/SF alone in experiment 1, which did not affect liver weight, were similar to those achieved by infusion of HGF/SF plus dextran sulfate in experiment 2, which did stimulate liver growth. The source of this variability is unclear but seems to be due more to interexperiment factors than interassay variability, because similar values were obtained when representative samples were rerun within a single assay. Because HGF/SF is very sticky, we think, for example, that the lower values in experiment 2 might be related to differences in sample collection and processing, such as the use of glass vs. plastic tubes, that were not appreciated in these early experiments. Nonetheless, all samples within an experiment were handled identically, and therefore we feel confident in comparing relative concentrations between groups within each experiment. This is supported by the fact that across all experiments, all samples from animals that had not been exposed to exogenous HGF/SF consistently read out extremely low in the ELISA, whereas those from animals infused with HGF/SF were always easily detectable and correlated with the dose of either HGF/SF or dextran sulfate (see Figs. 1 and 2) .
Even in the absence of the intraexperiment variability, it is difficult to try to compare the plasma levels we achieved with those that occur during liver regeneration. Most reports on changes in HGF/SF in liver regeneration have measured either mRNA or bioactivity. Lindroos et al. (11) found very high levels of immunoactive HGF/SF after partial hepatectomy in rats, but the assay was developed against rabbit HGF/ SF. The high levels in the assay may reflect poor cross-reactivity with rat HGF/SF. Low nanogram per milliliter levels have been detected in patients after surgical resection (22).
It was interesting that infusion of either HGF/SF alone (experiment 1, Table 1 ) or HGF/SF with a low concentration of dextran sulfate (Fig. 1 ) caused circulating HGF/SF concentrations to be increased but had no significant effect on liver weight. One explanation is that the effectiveness of low concentrations may be quenched by binding proteins, creating a threshold. Although circulating binding proteins for HGF/SF have not been reported, shed extracellular domains of membrane receptors are common as binding proteins, and a shed form of the extracellular domain of c-met, the HGF receptor, has been described by Prat and colleagues (20). Alternatively, dextran sulfate may act as more than a carrier to prevent matrix trapping, perhaps by having a stabilizing effect on HGF/SF as described above.
Using this delivery system, we have been able to induce growth of liver in an otherwise intact animal. While this work was in progress, Fujiwara et al. (6) reported that HGF stimulated liver growth in normal rats and enhanced the amount of liver regenerated after partial hepatectomy. In those studies, HGF was injected intravenously every 2 h for 10 h. Each injection was 10 kg/100 g body w-t, a total dose of 600 pg/kg. This dose is lower than the daily dose we found to be necessary to induce comparable liver growth in our studies, but it compares favorably when one considers that in our studies the material was delivered by continuous extravascular infusion, whereas in those of Fujiwara et al. (6) it was delivered directly into the bloodstream.
To our knowledge, these are the only two reports that a growth factor can induce growth of normal liver in vivo, despite the fact that a large number of proteins can stimulate hepatocyte DNA synthesis in vitro. In contrast, Webber et al. (24) infused HGF/SF directly into the portal vein and found minimal response unless the animals had undergone a one-third hepatectomy, which by itself had minimal effect on hepatic DNA synthesis. Doses of 40-80 kg/day were used. For comparison, our infusion dose of 2.4 mgvkg-'*day-l is equal to 60 pg/day, delivered extravascularly.
Therefore, we cannot explain the discrepancy by dose. However, our infusions lasted 3 days, whereas those of Webber et al. (24) lasted only 24 h. In addition, we included dextran sulfate, which may act as more than a carrier (see above). It is clear that one-third hepatectomy enhances hepatic sensitivity to HGF/SF, but the fact that both we and Fujiwara et al. (6) have induced liver growth without this step suggests that a priming step is not essential.
A major mechanism for the HGF/SF-induced increase in wet liver weight is hepatocyte proliferation. Mitotic figures, which were rarely observed in histological sections from control liver, were abundant in livers exposed to HGF/SF. Mitoses were found randomly distributed 
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throughout the hepatic lobule, with no apparent association with vascular elements. Although HGF/SF has been reported to stimulate DNA synthesis in nonparenchymal cells and bile duct epithelial cells in vitro (9), we observed no mitotic figures in bile duct epithelial cells. However, the number of such cells in any section is very small compared with the number of hepatocytes, so a modest amount of proliferation in this compartment would be difficult to detect histologically.
Hepatic DNA content was elevated in the HGFISFtreated animals in both experiments in which it was measured, although this did not reach statistical significance in experiment 5. The difference in DNA levels between these two experiments is due to the fact that polypropylene tubes were used for the DNA assay in experiment 5, whereas glass tubes were used for experiment 6; dissolution of the pellet after TCA precipitation was easier in glass tubes, giving better extraction efficiency.
There also appears to be a component of the increase in liver wet weight that is not related to proliferation. For example, a dose of 1.2 mg l kg-l l day-l clearly had no effect on mitotic activity (Table 3 ) but caused significant increases in liver wet weight (Table 3 ) and serum lipids (Table 4 ) and a significant decrease in alkaline phosphatase (Table 4) . Others have reported striking effects of HGF/SF on the morphology of several cell types (3, 10, 23), suggesting that it may have trophic as well as proliferative actions in target tissues. Our data are consistent with such a trophic action in the liver.
Expression of HGF/SF in the kidney has been shown to increase after unilateral nephrectomy, which has raised the suggestion that HGF/SF is important in compensatory renal hypertrophy (15). However, we consistently found no effect on kidney size, despite the fact that liver size was increased in every experiment. Infusions of longer duration have also shown no effects on kidney size (unpublished observation). The sensitivity of the kidney to HGF/SF may be regulated locally in different physiological states. Alternatively, the intraperitoneal infusion may have delivered higher concentrations to the liver than the kidney.
Lastly, we observed that HGF/SF-induced liver growth was associated with changes in serum biochemistry, the most striking of which was lipemia. Total protein and serum albumin were also markedly elevated. These changes might be predicted in view of the fact that the liver is a major source of plasma proteins and a regulator of lipid metabolism (2). The reason that alkaline phosphatase was reduced is unknown.
Nonetheless, these results indicate that HGF/SF has major effects on hepatic function, as well as size.
In conclusion, the data presented here show that intraperitoneal infusion of HGF/SF combined with dextran sulfate provides sustained elevations in circulating HGFISF levels, and the use of osmotic minipumps allows experiments to be conducted in untethered animals. In addition, we have shown that normal liver can be induced to grow by treatment with HGF/SF in the absence of any other perturbation or priming. The increase in liver size was accompanied by marked increases in proliferative activity of hepatocytes and in increases in the level of serum protein and lipid. This system should be useful in testing the actions of HGF/SF in other organ systems and experimental models, and the principle of using sulfated polysaccharides as delivery vehicles should be useful in other heparin-binding proteins.
